$ Value
$0
Shares
14,684
Price
$0
Filed
Jan 5
Insider
Name
Machiels Alec
Title
—
CIK
0001496687
Roles
Transaction Details
Transaction Date
2026-01-01
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
14,684
Footnotes
This restricted stock unit was granted on January 1, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election. | The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the "Trust"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust. | Owned by spouse. | On September 7, 2021, the reporting person's spouse transferred 150,000 shares of Apellis Pharmaceuticals, Inc. common stock to her trust, of which the reporting person is the trustee. | This option was granted on January 1, 2026. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.
Filing Info
Other Insiders at APLS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Dolsten Mikael | — | — | 2026-02-27 |
|
Watson David O.
General Counsel
|
— | — | 2026-01-28 |
|
Deschatelets Pascal
Chief Scientific Officer
|
— | — | 2026-01-28 |
|
Francois Cedric
Chief Executive Officer
|
— | — | 2026-03-11 |
|
Sullivan Timothy Eugene
Chief Financial Officer
|
— | — | 2026-04-17 |
| O'Brien Stephanie Monaghan | — | — | 2026-04-06 |
|
Nicholson Nur
Chief Technical Officer
|
— | — | 2026-01-28 |
|
Chopas James George
VP/Chief Accounting Officer
|
— | — | 2026-01-28 |
|
DeLong Mark Jeffrey
Chief Business & Strat Officer
|
— | $8K | 2026-02-11 |
|
Boucher Kelley
Chief People Officer
|
— | — | 2026-01-28 |
|
MELTZER LESLIE
Chief Research and Development
|
— | — | 2026-01-28 |